Cargando…

Remdesivir modifies interferon response in hospitalized COVID-19 patients

Detalles Bibliográficos
Autores principales:	Murphy, Sarah L., Halvorsen, Bente, Barratt-Due, Andreas, Dyrhol-Riise, Anne Ma, Aukrust, Pål, Trøseid, Marius, Dahl, Tuva B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338165/ https://www.ncbi.nlm.nih.gov/pubmed/35914611 http://dx.doi.org/10.1016/j.jinf.2022.07.021

Ejemplares similares

CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19
por: Gregersen, Ida, et al.
Publicado: (2022)

Assessing the evidence on remdesivir
por: Trøseid, Marius, et al.
Publicado: (2021)

Low-density lipoprotein particles carrying proinflammatory proteins with altered aggregation pattern detected in COVID-19 patients 3 months after hospitalization
por: Ueland, Thor, et al.
Publicado: (2023)

Severely ill COVID-19 patients have altered circulating levels of proteins controlling the epitranscriptome()
por: Quiles-Jiménez, A., et al.
Publicado: (2023)

Increased inflammatory markers reflecting fibrogenesis are independently associated with cardiac involvement in hospitalized COVID-19 patients
por: Ueland, T, et al.
Publicado: (2021)

Activated dendritic cells and monocytes in HIV immunological nonresponders: HIV-induced interferon-inducible protein-10 correlates with low future CD4(+) recovery
por: Stiksrud, Birgitte, et al.
Publicado: (2019)

High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19
por: Tveita, Anders, et al.
Publicado: (2022)

Persistent T‐cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID‐19: Results from two Norwegian cohort studies
por: Trøseid, Marius, et al.
Publicado: (2022)

Neutrophil count predicts clinical outcome in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial
por: Kåsine, Trine, et al.
Publicado: (2021)

Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responses
por: Feruglio, Siri L., et al.
Publicado: (2013)

DNA Repair Mechanisms are Activated in Circulating Lymphocytes of Hospitalized Covid-19 Patients
por: Olsen, Maria Belland, et al.
Publicado: (2022)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Gut Microbiota-Dependent Trimethylamine N-Oxide Associates With Inflammation in Common Variable Immunodeficiency
por: Macpherson, Magnhild E., et al.
Publicado: (2020)

Reduced Cardiac Function by Echocardiography in a Minority of COVID-19 Patients 3 Months after Hospitalization
por: Tangen, Jorun, et al.
Publicado: (2022)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Anaphylaxis Due to Remdesivir
por: Hopkins, Brian J., et al.
Publicado: (2021)

Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9
por: Lerum, Tøri Vigeland, et al.
Publicado: (2021)

Successful management of remdesivir extravasation
por: Conde-Estévez, David, et al.
Publicado: (2022)

Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19
por: Aamodt, Anne Hege, et al.
Publicado: (2021)

Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results
por: Gran, Gerd, et al.
Publicado: (2013)

Status of Remdesivir: Not Yet Beyond Question!
por: Chatterjee, Saptarshi
Publicado: (2021)

Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome
por: Barratt-Due, Andreas, et al.
Publicado: (2016)

Response to: Status of Remdesivir: Not Yet Beyond Question!
por: Saha, Abinit, et al.
Publicado: (2021)

Pulmonary administration of remdesivir in the treatment of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2020)

Remdesivir for COVID-19: Why Not Dose Higher?
por: Yan, Victoria C., et al.
Publicado: (2021)

Bradycardia due to remdesivir: Report of two cases()
por: Cebrián Lara, Laura, et al.
Publicado: (2022)

Remdesivir for the treatment of COVID-19: author's response
por: Lee, Todd C., et al.
Publicado: (2023)

SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity
por: Mohn, Kristin G-I, et al.
Publicado: (2023)

Liver injury in remdesivir-treated COVID-19 patients
por: Zampino, Rosa, et al.
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2022)

The impact of an antimicrobial stewardship program restriction on remdesivir prescribing
por: Zeitler, Kristen E., et al.
Publicado: (2022)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2023)

Indian perspective of remdesivir: A promising COVID-19 drug
por: Singh, Devendra, et al.
Publicado: (2020)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Re: Remdesivir for the treatment of COVID-19 by Lee et al.
por: Beccacece, Alessia, et al.
Publicado: (2023)

Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial
por: Prebensen, Christian, et al.
Publicado: (2017)

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response
por: Trøseid, Marius, et al.
Publicado: (2022)

Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver
por: Yan, Victoria C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_02vg6smf1ngpc8k3qeljvs1fqq